FDA-cleared profile

Prostate MR AI (VA10A)

Siemens Healthcare GmbH · MRI · FDA-cleared (510(k))

Authorized purpose: Prostate MR AI (VA10A) is a plug-in CADe/CADx aid for radiologists interpreting prostate MRI in adult men aged 40 years or older with suspected prostate cancer and no prior treatment, using PI-RADS-oriented review; it is not the sole basis for diagnosis or management.

Clinical role
Segments the prostate, highlights suspicious regions, provides lesion and case scores, and displays maps or measurements alongside radiologist review.
Images and patients
MRI · Prostate
Key limitation
Keep in mind: Use is limited to adult men aged 40 years or older with suspected cancer in a treatment-naive prostate and the supported MRI sequences; radiologist review remains required and the software is not the sole basis for a clinical decision.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Prostate MR AI (VA10A) is a plug-in CADe/CADx aid for radiologists interpreting prostate MRI in adult men aged 40 years or older with suspected prostate cancer and no prior treatment, using PI-RADS-oriented review; it is not the sole basis for diagnosis or management.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Prostate Input: Adult prostate MRI with noncontrast T2-weighted and diffusion-weighted sequences; additional MR data and DCE information may be available as described in the FDA material.
  • Who uses it?Intended users: Radiologists and other qualified physicians trained to interpret prostate MRI and PI-RADS-oriented findings.
  • What does the software produce?Output: Prostate segmentation, suspicious-region contours, lesion score or level-of-suspicion information, PI-RADS suggestion, suspicion maps, case-level score, and optional center, diameter, or ADC measurements.
  • What is its most important limitation?Key limitation: Use is limited to adult men aged 40 years or older with suspected cancer in a treatment-naive prostate and the supported MRI sequences; radiologist review remains required and the software is not the sole basis for a clinical decision.

Clinical takeaway. Clinical role: Prostate MR AI (VA10A) is a plug-in CADe/CADx aid for radiologists interpreting prostate MRI in adult men aged 40 years or older with suspected prostate cancer and no prior treatment, using PI-RADS-oriented review; it is not the sole basis for diagnosis or management.

Evidence takeaway. Evidence from the reviewed source record: The K241770 FDA material reports an MRMC reader study of 340 cases read by 12 ABR radiologists at two U.S. sites, plus standalone case cohorts of 105 and 115 cases; aided AUROC exceeded unaided AUROC in the reported fully inclusive and maximally restrictive analyses.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Prostate MR AI (VA10A) is a plug-in CADe/CADx aid for radiologists interpreting prostate MRI in adult men aged 40 years or older with suspected prostate cancer and no prior treatment, using PI-RADS-oriented review; it is not the sole basis for diagnosis or management.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Segments the prostate, highlights suspicious regions, provides lesion and case scores, and displays maps or measurements alongside radiologist review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Adult prostate MRI with noncontrast T2-weighted and diffusion-weighted sequences; additional MR data and DCE information may be available as described in the FDA material.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Prostate segmentation, suspicious-region contours, lesion score or level-of-suspicion information, PI-RADS suggestion, suspicion maps, case-level score, and optional center, diameter, or ADC measurements.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospital or radiology-facility prostate MRI interpretation workflows.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Radiologists and other qualified physicians trained to interpret prostate MRI and PI-RADS-oriented findings.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Use is limited to adult men aged 40 years or older with suspected cancer in a treatment-naive prostate and the supported MRI sequences; radiologist review remains required and the software is not the sole basis for a clinical decision.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The K241770 FDA material reports an MRMC reader study of 340 cases read by 12 ABR radiologists at two U.S. sites, plus standalone case cohorts of 105 and 115 cases; aided AUROC exceeded unaided AUROC in the reported fully inclusive and maximally restrictive analyses.
  • Exact FDA submission
  • Checked 2026-09-04

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The K241770 FDA material reports an MRMC reader study of 340 cases read by 12 ABR radiologists at two U.S. sites, plus standalone case cohorts of 105 and 115 cases; aided AUROC exceeded unaided AUROC in the reported fully inclusive and maximally restrictive analyses.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

MRMC fully inclusive AUROC, unaided

0.6758 AUROC

  • EndpointReader-study case-level discrimination
  • Population340-case MRMC prostate MRI study read by 12 ABR radiologists
  • Tested versionProstate MR AI (VA10A) configuration described in K241770

MRMC fully inclusive AUROC, aided

0.701 AUROC

  • EndpointReader-study case-level discrimination with software aid
  • Population340-case MRMC prostate MRI study read by 12 ABR radiologists
  • Tested versionProstate MR AI (VA10A) configuration described in K241770

MRMC AUROC aided-minus-unaided difference

0.0252 AUROC difference

  • EndpointReported paired reader-study AUROC difference
  • Population340-case MRMC prostate MRI study
  • Tested versionProstate MR AI (VA10A) configuration described in K241770

Case threshold >=3 sensitivity, aided

0.6 proportion

  • EndpointCase-level sensitivity at threshold >=3
  • PopulationFully inclusive MRMC prostate MRI analysis
  • Tested versionProstate MR AI (VA10A) configuration described in K241770

Case threshold >=3 specificity, aided

0.73 proportion

  • EndpointCase-level specificity at threshold >=3
  • PopulationFully inclusive MRMC prostate MRI analysis
  • Tested versionProstate MR AI (VA10A) configuration described in K241770

K241770 FDA evidence package for Prostate MR AI (VA10A)

  • DesignFDA 510(k) standalone performance and multi-reader multi-case reader study for prostate MRI interpretation support.
  • Population340 prostate MRI cases read by 12 ABR radiologists at two U.S. sites, with separate radiology-ground-truth and biopsy-ground-truth cohorts.
  • Scopeexact submission
  • Tested versionProstate MR AI (VA10A) configuration described in K241770
  • Samplen=340
  • Sites2
  • IndependenceSponsor or vendor study

K241770

The FDA material reports reader-level and case-level endpoints; values are tied to the stated version, population, protocol, and reader study.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K241770 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult prostate MRI with noncontrast T2-weighted and diffusion-weighted sequences; additional MR data and DCE information may be available as described in the FDA material.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K241770: Prostate MR AI (VA10A)

  2. Routing

    Source context, not route validation: The FDA material describes a plug-in with a separate host application and supported prostate MRI inputs, with displayed contours, maps, scores, and measurements for radiologist review.

    Scope: Exact FDA submission. This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K241770: Prostate MR AI (VA10A)

  3. AI processing

    Source context, not route validation: The FDA material describes a separate hosting application or plug-in and a syngo.MR General Engine license; the current host topology, security, service, and local configuration remain unverified.

    Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA decision material; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K241770: Prostate MR AI (VA10A)

  4. Returned objects

    Source context, not route validation: Prostate segmentation, suspicious-region contours, lesion score or level-of-suspicion information, PI-RADS suggestion, suspicion maps, case-level score, and optional center, diameter, or ADC measurements.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K241770: Prostate MR AI (VA10A)

  5. Viewer/worklist/report

    Unresolved route: Prostate segmentation, suspicious-region contours, lesion score or level-of-suspicion information, PI-RADS suggestion, suspicion maps, case-level score, and optional center, diameter, or ADC measurements.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K241770: Prostate MR AI (VA10A)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA material describes a separate hosting application or plug-in and a syngo.MR General Engine license; the current host topology, security, service, and local configuration remain unverified.
  • Exact FDA submission
  • Checked 2026-09-04

This is the release-level boundary described in the exact FDA decision material; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

Integration
The FDA material describes a plug-in with a separate host application and supported prostate MRI inputs, with displayed contours, maps, scores, and measurements for radiologist review.
  • Exact FDA submission
  • Checked 2026-09-04

This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Security
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.

Training
Only Radiologists and other qualified physicians trained to interpret prostate MRI and PI-RADS-oriented findings should operate or interpret the product; local onboarding must cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K241770 by exact hardware, software, model, algorithm version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Use is limited to adult men aged 40 years or older with suspected cancer in a treatment-naive prostate and the supported MRI sequences; radiologist review remains required and the software is not the sole basis for a clinical decision.
  • Exact FDA submission
  • Checked 2026-09-04

Buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K241770 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The FDA material describes a separate hosting application or plug-in and a syngo.MR General Engine license; the current host topology, security, service, and local configuration remain unverified.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA material describes a plug-in with a separate host application and supported prostate MRI inputs, with displayed contours, maps, scores, and measurements for radiologist review.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Use is limited to adult men aged 40 years or older with suspected cancer in a treatment-naive prostate and the supported MRI sequences; radiologist review remains required and the software is not the sole basis for a clinical decision.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K241770 by exact hardware, software, model, algorithm version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K241770
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Prostate
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-03-05
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
32Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The discovery snapshot contains no PubMed or ClinicalTrials.gov candidates for K241770; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K241770: Prostate MR AI (VA10A)

    U.S. Food and Drug Administration - Published 2025-03-05 - Accessed 2026-09-04

    Scope: identity, productIdentity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Siemens Healthineers: Cybersecurity

    Siemens Healthineers - Accessed 2026-10-26

    Scope: security

Research history

  1. K241770 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K242683

QP-Prostate® CAD

Quibim S.L.

Authorized purpose: QP-Prostate CAD detects and marks suspected prostate lesions for clinically significant prostate cancer on bi-parametric T2-weighted and diffusion-weighted prostate MRI, returning moderate/high suspicion overlays in DICOM to third-party workstations/PACS for concurrent physician review; patient management must not rely on it alone.

Modality
MRI
Anatomy
Prostate
Decision
2025-03-18
FDA-cleared K212783

ProstatID

ScanMed, LLC

Authorized purpose: Concurrent CADe/CADx reading aid for qualified physicians interpreting prostate MRI in adult males undergoing screening or clinical MRI, including high-risk screening or diagnostic imaging, to identify prostate abnormalities and regions suspicious for cancer and assess their likelihood of malignancy.

Modality
MRI
Anatomy
Prostate
Decision
2022-07-08
FDA-cleared K233196

Medihub Prostate

JLK Inc.

Authorized purpose: Assist trained radiologists and urologists in reviewing and analyzing prostate MR studies through semi-automatic prostate outlining, multiparametric visualization, and related measurements and reporting; patient-management decisions must not rely on the software alone.

Modality
MRI
Anatomy
Prostate
Decision
2024-06-21

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history